Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568167 | 0.86 | PRKAA2 (0.51) | SMYD3PRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL178410 | 0.80 | CNR1 (0.52) | SMYD3PRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL18373773 | 0.79 | HDAC6 (0.52) | PARP1MAPTMAPK14SMN1; SMN2NPC1 | |
| SCHEMBL12561176 | 0.79 | PLK1 (0.55) | PARP1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12291731 | 0.79 | MAPT (0.46) | MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL506648 | 0.78 | ALDH1A1 (0.50) | SMYD3PRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL16047520 | 0.78 | MAPK1 (0.64) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL17253106 | 0.78 | PRKAB2 (0.48) | SMYD3PRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL27308715 | 0.78 | MAPT (0.49) | PARP1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL9908372 | 0.78 | PARP1 (0.53) | PARP1MAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | SMYD3 4484/4885PRKAA2 232/4885PRKAB2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.